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The transcription factor NF-κB has served as a standard for inducible transcription factors for 
more than 20 years. The numerous stimuli that activate NF-κB, and the large number of genes 
regulated by NF-κB, ensure that this transcription factor is still the subject of intense research. 
Here, we attempt to synthesize some of the basic principles that have emerged from studies of 
NF-κB, and we aim to generate a more unified view of NF-κB regulation.Introduction
Twenty years following the identification 
of nuclear factor-κB (NF-κB) as a regu-
lator of expression of the κB light chain 
in B cells, research into the function and 
regulation of the NF-κB family contin-
ues at a blistering pace. Advances in 
understanding how the immune system 
senses pathogens and processes this 
information through the activation of 
NF-κB, as well as an ever-expanding list 
of diseases in which dysregulation of 
NF-κB has been implicated, have con-
tinued to invite broad interest into the 
regulation of this inducible transcription 
factor. A PubMed search reveals close 
to 30,000 papers and, staggeringly, 
nearly 3,000 reviews related to NF-κB. 
Why then, one more? Part of the answer 
lies in these numbers themselves. The 
sheer volume of work in this area has 
allowed the field of NF-κB research to 
be both a source of signaling paradigms 
that have been broadly applied to other 
systems, as well as a melting pot in 
which ideas from disparate fields have 
merged, been modified, and matured 
into new concepts. Here we attempt to 
unify some of the recent advances into a 
cohesive framework encompassing key 
principles governing NF-κB signaling 
that illustrate this give and take.
The inducible regulation of gene 
expression is a central element of nor-
mal physiology and is the key to the abil-
ity of multicellular organisms to adapt to 
environmental, mechanical, chemical, 
and microbiological stresses. Owing 
to its amenability to experimentation 
and its importance in disease, NF-κB 
has served as a model of cell, tissue, 344 Cell 132, February 8, 2008 ©2008 ElseFigure 1. NF-κB Signaling Pathways
Following receptor ligation and recruitment of re-
ceptor proximal adaptor proteins, signaling to IKK 
proceeds through TRAF/RIP complexes, generally 
in conjunction with TAK1, leading to canonical NF-
κB signaling, or through TRAFs and NIK leading to 
the noncanonical NF-κB pathway. IKK activation 
results in IκB phosphorylation and degradation in 
the canonical pathway or p100 processing to p52 
in the noncanonical pathway. Phosphorylated NF-
κB dimers bind to κB DNA elements and induce 
transcription of target genes.vier Inc.and organism level responses that are 
orchestrated through inducible tran-
scription factors. NF-κB plays its most 
important and evolutionarily conserved 
role in the immune system, regulating the 
expression of inducers and effectors at 
many points in the expansive networks 
that define responses to pathogens. Con-
sequently much of our understanding of 
NF-κB is derived from studying immu-
nologically relevant signaling pathways. 
The reach of NF-κB, however, extends 
to transcriptional regulation beyond the 
confines of the immune response, act-
ing broadly to influence gene expression 
events that impact cell survival, differen-
tiation, and proliferation.
The diversity of biological roles ful-
filled by NF-κB raises several intrigu-
ing questions about how a limited set of 
signal transduction molecules regulates 
signaling to NF-κB in all pathways and, 
conversely, how discrete inputs create 
transcriptional responses tailored to par-
ticular tissues and organs with the same 
limited set of regulators. One corollary 
of so many pathways coalescing on one 
transcription factor, however, is that dys-
regulation of its function can have broad 
deleterious consequences. Indeed, the 
literature is filled with reports implicating 
dysregulation of NF-κB in various patho-
logical situations (Courtois and Gilmore, 
2006; Karin, 2006).
The progressively increasing size of the 
NF-κB literature has made writing a com-
prehensive review on NF-κB a daunting, 
if not untenable, undertaking. Instead, in 
the current Review we have attempted to 
highlight aspects of NF-κB regulation and 
function that reflect the broad physiologi-
cal and medical significance of this transcription factor and in 
particular focus on those areas that we feel are undergoing 
significant progress, e.g., regulatory mechanisms that illustrate 
shared principles that are likely to extend to pathways beyond 
those affecting NF-κB. We have organized this Review around 
the core components of the NF-κB pathway, namely the IKK 
complex, the inhibitory IκB proteins, and the transcription fac-
tor NF-κB itself. Thus the first section will deal with commonali-
ties in signaling to IKK; the second with the organization and 
activation of IKK; the third with the emerging dualistic roles of 
IκB proteins; and the fourth with the interface between NF-κB 
and chromatin in the regulation of transcription.
Background
The basic scheme of NF-κB signaling consists of a series of 
positive and negative regulatory elements. Inducing stimuli trig-
ger IKK activation leading to phosphorylation, ubiquitination, 
and degradation of IκB proteins (Figure 1). Released NF-κB 
dimers are further activated through various posttranslational 
modifications and translocate to the nucleus where they bind 
to specific DNA sequences and promote transcription of target 
genes. In its most basic form, therefore, the pathway consists 
of receptor and receptor proximal signaling adaptor molecules; 
the IKK complex; IκB proteins; and NF-κB dimers.
The NF-κB family of transcription factors consists of five 
members, p50, p52, p65 (RelA), c-Rel, and RelB, encoded by 
NFKB1, NFKB2, RELA, REL, and RELB, respectively, which 
share an N-terminal Rel homology domain (RHD) responsible 
for DNA binding and homo- and heterodimerization (Figure 2). 
NF-κB dimers bind to κB sites within the promoters/enhanc-
ers of target genes and regulate transcription through the 
recruitment of coactivators and corepressors. The transcrip-
tion activation domain (TAD) necessary for the positive regu-
lation of gene expression is present only in p65, c-Rel, and 
RelB. As they lack TADs, p50 and p52 may repress transcrip-
tion unless associated with a TAD-containing NF-κB family 
member or other proteins capable of coactivator recruitment. 
Constitutive binding of p50 or p52 homodimers to κB sites on 
NF-κB-responsive promoters may thus act to check NF-κB 
transactivation until displaced by transcriptionally competent 
NF-κB dimers.
There is considerable structural information about NF-κB 
dimers in both its inactive IκB-bound form and active DNA 
bound state. Crystal structures of NF-κB dimers bound to κB 
sites reveal how the immunoglobulin-like domains that comprise 
the RHD contact DNA. The NH2-terminal Ig-like domain confers 
selectivity for certain types of κB sites, whereas the hydropho-
bic residues within the C-terminal domain provide the dimeriza-
tion interface between NF-κB subunits (Hoffmann et al., 2006). 
Unfortunately the three-dimensional structure of the C-terminal 
TAD has not been determined yet, most likely due to the disor-
dered nature of the protein in this region. Although RHD and TAD 
function are typically considered independent, both domains 
undergo posttranslational modifications that can affect NF-κB 
transcriptional activity as well as DNA binding (Figure 2).
In its inactive state, NF-κB dimers are associated with one 
of three typical IκB proteins, IκBα (NFKBIA), IκBβ (NFKBIB), 
or IκBε (NFKBIE ), or the precursor proteins p100 (NFKB2) Figure 2. The NF-κB, IκB, and IKK Protein Families
Members of the NF-κB, IκB, and IKK proteins are shown. The number of 
amino acids in each human protein is indicated on the right. Posttransla-
tional modifications that influence IKK activity or transcriptional activa-
tion are indicated with P, U, or Ac for phosphorylation, ubiquitination, or 
acetylation, respectively. Inhibitory events and phosphorylation and ubiq-
uitination sites on p100, p105, and IκB proteins that mediate proteasomal 
degradation are indicated with red Ps and Us, respectively. RHD, Rel ho-
mology domain; TAD, transactivation domain; LZ, leucine zipper domain; 
GRR, glycine-rich region; HLH, helix-loop-helix domain; Z, zinc finger 
domain; CC1/2, coiled-coil domains; NBD, NEMO-binding domain; MOD/
UBD, minimal oligomerization domain and ubiquitin-binding domain; and 
DD, death domain.Cell 132, February 8, 2008 ©2008 Elsevier Inc. 345
and p105 (NFKB1). These IκBs maintain NF-κB dimers in the 
cytoplasm and are crucial for signal responsiveness. There 
are two inducibly expressed, atypical IκB proteins, Bcl-3 
(BCL3) and IκBζ (NFKBZ ), that function quite differently in 
the regulation of NF-κB (discussed below). Lastly an alter-
native transcript of the NFKB1 gene in mouse encodes an 
IκB molecule, IκBγ, whose biological role remains unclear. 
All IκB proteins are characterized by the presence of mul-
tiple ankyrin repeat domains (Figure 2). The prototypical and 
most extensively studied member of the family is IκBα. IκBα 
is rapidly degraded during activation of canonical NF-κB 
signaling pathways leading to the release of multiple NF-κB 
dimers, although the p65:p50 heterodimer is likely the pri-
mary target of IκBα. The established model of IκB function 
posits that IκBα retains NF-κB dimers in the cytoplasm, 
thereby preventing their nuclear translocation and subse-
quent DNA binding; however, the situation is actually more 
complex. The crystal structure of IκBα bound to the p65/
p50 heterodimer reveals that the IκBα protein masks only 
the nuclear localization sequence (NLS) of p65, whereas 
the NLS of p50 remains exposed. The exposed NLS of p50 
coupled with nuclear export sequences (NES) in IκBα and 
p65 leads to constant shuttling of IκBα/NF-κB complexes 
between the nucleus and the cytoplasm, despite steady-
state localization that appears almost exclusively cytosolic 
(Ghosh and Karin, 2002). Degradation of IκBα drastically 
alters the dynamic balance between cytosolic and nuclear 
localization signals to favor nuclear localization of NF-κB. 
The noncanonical or alternative NF-κB pathway, however, 
proceeds through proteasomal processing, rather than deg-
radation, of p100 to p52, thereby liberating p52 containing 
NF-κB dimers that drive a transcriptional response that is 
distinct from that induced by the canonical, IκBα-regulated 
pathway. In part because IκBα degradation and p100 pro-
cessing regulate different populations of NF-κB dimers, 
canonical and noncanonical NF-κB pathways regulate dis-
tinct sets of target genes.
Degradation of IκB is a rapidly induced signaling event that 
is initiated upon specific phosphorylation of these molecules 
by activated IKK. The IKK complex contains two highly homol-
ogous kinase subunits, IKKα/IKK1 (CHUK) and IKKβ/IKK2 
(IKBKB), and a regulatory subunit NEMO (NF-κB essential 
modulator)/IKKγ (IKBKG) (Hacker and Karin, 2006). Although 
they are generally found in a heteromeric kinase complex, IKKα 
and IKKβ are somewhat selectively required for specific NF-κB 
signaling pathways. In most canonical NF-κB signaling, e.g., 
downstream of TNFR1, IKKβ is both necessary and sufficient 
for phosphorylation of IκBα on Ser32 and Ser36 and of IκBβ on 
Ser19 and Ser23. While not generally required for IκBα phos-
phorylation and degradation in canonical signaling pathways, 
IKKα can mediate IκBα phosphorylation and appears to play 
a critical role in canonical NF-κB-dependent transcriptional 
responses (discussed below). The noncanonical pathway, con-
versely, depends only on the IKKα subunit, which functions by 
phosphorylating p100 and causing its inducible processing 
to p52. The noncanonical pathway is activated by a subset of 
TNFR superfamily members, while the canonical pathway is 
activated by a broader and overlapping array of receptors.346 Cell 132, February 8, 2008 ©2008 Elsevier Inc.Phosphorylation of the conserved serine residues 
(DS*GXXS*) in IκB proteins results in their K48-linked polyu-
biquitination by βTrCP containing Skp1-Culin-Roc1/Rbx1/
Hrt-1-F-box (SCF) E3 ubiquitin ligase complexes (SCFβTrCP) 
coordinately with the E2 UbcH5 (Perkins, 2006). The released 
NF-κB dimers bind promoter and enhancer regions contain-
ing κB consensus sequences 5′ GGGRNWYYCC 3′ (N—any 
base; R—purine; W—adenine or thymine; and Y—pyrimidine) 
(Hoffmann et al., 2006). The degenerate nature of the κB site 
sequence, which shows far greater sequence variability than 
the consensus sequence given here, combined with the var-
ied binding preferences of NF-κB dimers yields the large list of 
NF-κB-regulated genes (Gilmore, 2008). Transcription of target 
genes is further regulated through posttranslational modifica-
tions of NF-κB that affect the ability of NF-κB dimers to interact 
with transcriptional coactivators. NF-κB-dependent transcrip-
tion of IκB proteins as well as additional mechanisms targeting 
DNA-bound NF-κB dimers terminate the response.
Signaling to IKK
A remarkable diversity of stimuli lead to activation of NF-κB. 
These include both endogenous and exogenous ligands as 
well as a plethora of physical and chemical stresses (Gilmore, 
2008). There has been great progress in identifying the protein 
components of pathways that culminate in IKK activation and 
many of the remaining gaps in our knowledge are being rapidly 
filled in. However, while the identities of these molecules pro-
vide critical clues, much remains to be done to understand the 
mechanism(s) of IKK activation.
Strikingly, work in numerous signaling pathways leading 
to NF-κB has demonstrated that many of the signaling inter-
mediates, especially those just upstream of the IKK complex, 
are shared. Signaling to NF-κB proceeds through intracellular 
adaptor proteins that provide modularity to NF-κB activation 
pathways and allows their incorporation into various receptor-
induced signaling events. Thus diverse signaling pathways can 
utilize several shared components for both activating and inhib-
itory pathways. In particular, RIP and TRAF families of proteins 
play similar roles in most pathways that lead to IKK activation 
(Figure 1). Although there are exceptions, some of which are 
noted below, it appears that both canonical and noncanoni-
cal pathways utilize TRAF family members for activation, while 
only canonical, NEMO-dependent signaling to typical IκBs 
additionally requires RIP proteins.
The core elements of NF-κB signaling pathways are gener-
ally several steps removed from the receptor itself. The inter-
vening steps between receptor and IKK form links to parallel 
signaling pathways. For example, IL-1R and RIG-I, which both 
signal through TRAF6 to IKK, do so through distinct recep-
tor proximal adaptor components MyD88 and MAVS, respec-
tively (Hacker and Karin, 2006). Thus when IL-1R binds IL-1 
or RIG-I binds cytoplasmic dsRNA they activate overlapping 
but unique signaling pathways due to these differences in 
upstream signaling components, and hence they induce dis-
tinct transcriptional programs. It is important to bear in mind 
that although diverse upstream events may mediate IKK acti-
vation through a common mechanism, parallel signaling path-
ways emanating from nonredundant receptor proximal sig-
naling components frequently produce crosstalk that shapes 
the NF-κB response in ways that are unique to individual sig-
naling pathways.
One striking area of growth in the field of NF-κB signaling 
has been in the characterization of the role of K63-linked, or 
regulatory, ubiquitination. This area of research began with the 
biochemical characterization of TRAF6 as an E3 ligase that 
with the E2 ligase Ubc13/Uev1A could catalyze the formation 
of regulatory ubiquitin chains and induce IKK activation in vitro 
(Deng et al., 2000). Subsequently, several signaling compo-
nents have been shown to be modified by K63-linked ubiq-
uitin moieties following stimulation (Chen et al., 2006). While 
there are numerous reports demonstrating K63 ubiquitination 
of various signaling proteins, what continues to be lacking is an 
understanding of how regulatory ubiquitination functions dur-
ing signaling. The delayed kinetics of regulatory ubiquitination 
and the observation that it often targets a very small fraction 
of any given protein, even within signaling complexes, suggest 
that K63 ubiquitination may be a consequence of certain adapt-
ers with E3 ligase activity aggregating with other proteins dur-
ing NF-κB signaling. Even for particularly robustly and rapidly 
ubiquitinated adapters such as IRAK1 and MALT1, it is unclear 
whether K63-linked ubiquitination occurs before IKK activation 
and IκBα degradation (Oeckinghaus et al., 2007; Windheim 
et al., 2008). Because K63-linked ubiquitination has not been 
clearly shown to precede IKK activation, it remains to be deter-
mined whether these events are intrinsic to the act of signaling 
or necessary for the competence of the signaling pathways in 
which they occur. One piece of evidence that strongly suggests 
that K63 ubiquitination does play an active role in signaling is 
the existence of several deubiquitinases (DUBs), most notably 
A20, that provide negative feedback in NF-κB signaling path-
ways (Chen et al., 2006). More genetic evidence and mechanis-
tic insight are still needed for the centrality of regulatory ubiq-
uitination in NF-κB signaling to be unequivocally accepted.
TRAFs—Adapters in Most NF-κB Pathways
TRAFs are key intermediates in nearly all NF-κB signaling 
pathways; the DNA-damage response appears to be the 
only notable exception (Hacker and Karin, 2006; Scheidereit, 
2006). There are seven TRAF proteins that share a C-terminal 
TRAF domain, consisting of a coiled-coil domain that medi-
ates both homo- and heterotypic protein-protein interactions. 
In addition, TRAFs 2–7 have N-terminal RING finger domains 
that may function as E3 ubiquitin ligases by catalyzing the 
transfer of ubiquitin to target proteins—a function that has 
been demonstrated most clearly for TRAFs 2 and 6. Among 
the TRAF proteins, TRAF2, TRAF5, and TRAF6 have been 
most extensively characterized as positive regulators of sig-
naling to NF-κB. Research focused on the role of K63-linked 
ubiquitination in NF-κB signaling over the past 7 years has 
established an important role for TRAF E3 ligase activity in 
the activation of the IKK complex leading to both canonical 
and noncanonical NF-κB pathways and demonstrated the 
existence of K63 ubiquitination of multiple pathway compo-
nents (Chen et al., 2006). In addition to NF-κB, TRAF pro-
teins are necessary in several other pathways, e.g., AP-1, 
and therefore serve as branch points downstream of multiple 
receptors. The highly studied TNFR1 and Toll/IL-1R signaling pathways have provided the clearest evidence of the function 
of TRAF proteins in IKK activation (Hacker and Karin, 2006; 
Hayden et al., 2006).
Following binding of TNFα, TRAF2 is recruited to TNFR1 
through its interaction with TRADD (Hsu et al., 1996). However, 
despite deficiencies in AP-1 activation, TRAF2-deficient cells 
have relatively intact TNF signaling to NF-κB (Yeh et al., 1997). 
TRAF5 was also shown to interact with the TNFR1 signaling 
complex, yet TRAF5 knockouts also exhibit normal NF-κB 
activation by TNF; TRAF2/5 double knockout cells, however, 
are defective in IKK activation (Nakano et al., 1999; Tada et al., 
2001; Yeh et al., 1997). While the E3 ligase activity of TRAF2 
is thought to be required for IKK activation there are several 
caveats to this assumption. First, deletion of the RING finger 
domain abrogates the ability of TRAF2 to recruit IKK to the 
receptor complex making it difficult to assess the importance 
of TRAF2 E3-ligase activity independent of adaptor function in 
NF-κB activation (Devin et al., 2000). Second, knockdown of the 
K63-specific E2 ligase Ubc13 blocks TRAF2 autoubiquitination 
but not activation of NF-κB, while ubc13−/− macrophages show 
a similar lack of effect on NF-κB activation (Habelhah et al., 
2004; Yamamoto et al., 2006a). Intriguingly, another group did 
observe partial defects in TNF signaling to NF-κB in ubc13+/− 
heterozygous macrophages and splenocytes (Fukushima et 
al., 2007). Therefore, in TNFR1 signaling the function of TRAF2 
ubiquitin ligase activity remains to be more definitively estab-
lished. It is, however, safe to conclude that TRAF2 and TRAF5 
are together required for NF-κB activation by TNFR1.
In Toll/IL-1 signaling TRAF6 is recruited to the receptor com-
plex and is necessary for MyD88-dependent activation of 
NF-κB by IL-1 and ligands of TLR4 (Hacker and Karin, 2006; 
Hayden et al., 2006). However, like TRAF2, the importance of the 
E3-ligase activity of TRAF6 remains controversial. Reconstitu-
tion of TRAF6-deficient cells with a TRAF6 mutant lacking the 
signature motif of E3 RING-finger ligases—that is, the RING fin-
ger itself—completely restored IL-1-induced activation of NF-κB 
but not activation of JNK (Kobayashi et al., 2001). More recently, 
however, it has been shown that a ring finger point muta-
tion of TRAF6 is unable to restore NF-κB activation in TRAF6 
knockout cells (Lamothe et al., 2007). Therefore, the role of the 
TRAF6 E3 activity is yet to be definitively established. Deletion 
of Ubc13, likewise, yields conflicting results. Ubc13 knockouts 
failed to show significant defects in TRAF6-mediated activa-
tion of NF-κB downstream of LPS, IL-1, CD40, or BAFF despite 
impaired MAPK activation (Yamamoto et al., 2006a). Heterozy-
gous splenocytes and macrophages, however, showed a mild 
defect in LPS-induced IκBα degradation, less severe than the 
loss of p38 phosphorylation, and in these mice BCR signaling to 
NF-κB appeared normal (Fukushima et al., 2007). In T cell recep-
tor signaling, conditional ablation of Ubc13 resulted in a partial, 
but significant, reduction in NF-κB activation, although activa-
tion of JNK and TAK1 was more severely impaired (Yamamoto 
et al., 2006b). Therefore, it is probably too early to draw a defini-
tive conclusion about the general role of TRAF/Ubc13-mediated 
ubiquitination in IKK activation.
In addition to TRAF2 and TRAF6, the ubiquitin ligase activ-
ity of TRAF3 has been reported to regulate NF-κB signaling 
pathways. The noncanonical NF-κB pathway is characterized Cell 132, February 8, 2008 ©2008 Elsevier Inc. 347
by processing of p100 to p52 and by its independence from 
IKKβ and NEMO. Instead the alternative pathway relies on the 
activation of IKKα by the NF-κB-inducing kinase (NIK) (Hacker 
and Karin, 2006; Scheidereit, 2006). TRAF3, which interacts 
with receptors that trigger the alternative pathway (Hauer et al., 
2005), also interacts with NIK and it now appears that the acti-
vation of NIK is negatively regulated by TRAF3. In the resting 
state, TRAF3 induces NIK ubiquitination and degradation, but 
upon stimulation TRAF3 undergoes signal-dependent degra-
dation, mediated by other TRAF family members, resulting in 
the accumulation and activation of NIK and consequent activa-
tion of the noncanonical pathway (Liao et al., 2004). Recently 
this negative role of TRAF3 has been demonstrated genetically 
by rescuing the lethality of TRAF3-deficient mice by deleting 
the p100 gene (He et al., 2006). It remains unclear how alter-
native pathway signaling through degradation of TRAF3 might 
affect the ability of TRAF3 to fulfill its additional role as a key 
mediator of TLR-induced type I interferon responses (Hacker 
et al., 2006; Oganesyan et al., 2006).
Thus, TRAF proteins seem to play a crucial role in receptor-
induced IKK activation in both canonical and noncanonical 
pathways. It remains unclear whether they act primarily by cat-
alyzing K63-linked ubiquitination or as adaptor proteins. TRAF 
proteins may directly recruit the IKK complex through IKKα or 
IKKβ binding (Devin et al., 2001), although in most signaling 
pathways additional IKK recruitment mechanisms have been 
reported. For example, in antigen receptor signaling IKK can 
be recruited through an interaction with PKC family members 
while in TNFR1 signaling, IKK may be recruited to the receptor 
complex through the RIP1 kinase. The key remaining questions 
are to address the mechanism(s) by which TRAF proteins con-
tribute to IKK activation, particularly in conjunction with RIP 
proteins, and their contributions to NF-κB pathways in which 
their role has not yet been definitively established.
RIPs—Key Adapters in Canonical NF-κB Signaling
Receptor-interacting proteins (RIPs) appear to act both 
upstream of and with TRAF proteins to activate IKK. RIP pro-
teins act as true adapters in NF-κB signaling pathways by 
interacting with upstream signaling cassettes through well-
characterized protein-binding domains and recruiting the IKK 
complex through NEMO binding. RIP family members have 
been implicated in most TRAF-dependent pathways, e.g., 
signaling from TNFR superfamily and Toll/IL-1R. Additionally, 
there are also several pathways in which RIP family members 
are important, even though the requirement for TRAFs is less 
clear. These RIP-dependent/TRAF-independent IKKβ activa-
tion pathways may include antigen receptor signaling as well 
as signaling in response to DNA damage.
There are seven RIP family kinases that are characterized 
by their conserved serine/threonine kinase domains (Meylan 
and Tschopp, 2005). RIP1 and RIP3 also share the RIP homo-
typic interaction motif (RHIM). RIP1 possesses a death domain 
(DD), which mediates interaction with other death domain-con-
taining adapters and receptors. RIP3 was thought to function 
coordinately with RIP1, through RHIM-mediated interactions; 
however most NF-κB signaling pathways are normal in the 
absence of RIP3 (Newton et al., 2004). Instead, RIP3 may inter-
act with and repress RIP1-induced NF-κB activation in spe-348 Cell 132, February 8, 2008 ©2008 Elsevier Inc.cific instances (Meylan et al., 2004). RIP2 contains a C-terminal 
caspase activation and recruitment domain (CARD) that like-
wise mediates interactions with certain receptors and adap-
tors. RIP family members have also been implicated in canoni-
cal NF-κB signaling pathways where they appear to function 
in the TRAF-independent recruitment of the IKK complex by 
directly interacting with NEMO. Because the kinase activity of 
RIP1 and RIP2 has been shown to be dispensable for some 
NF-κB-activating pathways, it is thought that RIPs may act as 
adapters and scaffolds in facilitating TRAF-induced IKK activa-
tion (Lee et al., 2004; McCarthy et al., 1998). Similar to TRAFs, 
the TNFR1 signaling pathway has served as a model of RIP 
function in NF-κB activation.
RIP1 binds to NEMO and is essential for TNFα-induced IKK 
and NF-κB activation (Hsu et al., 1996; Kelliher et al., 1998; Ting 
et al., 1996; Zhang et al., 2000). In the absence of RIP1, IKK 
recruitment occurs through TRAF2 but does not lead to IKK 
activation (Devin et al., 2001). Thus RIP1 has a role that extends 
beyond the simple recruitment of the IKK complex. Although 
a typical phosphorylation cascade might have provided an 
appealing mechanism for RIP action, surprisingly RIP1 kinase 
activity was shown to be dispensable for IKK activation (Lee 
et al., 2004). RIP1 may instead nucleate the assembly of a sig-
naling complex that induces IKK activation through oligomer-
ization of NEMO and subsequent autophosphorylation of IKK 
(Delhase et al., 1999). Recent reports have indicated that this 
event might serve as a paradigm for the role of regulatory ubiq-
uitination in signaling. RIP1 is inducibly ubiquitinated by TRAF2 
following TNFα stimulation, and it has been reported that the 
mutation of acceptor lysines on RIP1 abrogates NEMO binding 
and IKK activation (Ea et al., 2006; Li et al., 2006a). A careful 
analysis of these data, however, suggests that the RIP1 lysine 
acceptor mutants that fail to be ubiquitinated also do not asso-
ciate with TNFR1, thereby leaving the role of RIP1 ubiquitina-
tion unclear (Ea et al., 2006). Furthermore, while TNFα-induced 
RIP1 ubiquitination appears to be completely abolished in 
traf2−/− cells, TNFα-induced IKK activation remains partly intact 
(Lee et al., 2004). In TNFR1 signaling, therefore, there is a clear 
requirement for RIP1 acting as an adaptor protein mediating 
IKK recruitment and activation, although the mechanism by 
which activation is achieved remains unclear.
In addition to TNFR1 signaling, and IKK activation via other 
death domain-containing TNFR family members, RIP1 has also 
been reported to be required for TRIF-dependent NF-κB acti-
vation via TLR3 and TLR4, as well as for NF-κB activation via 
RIG-I (Cusson-Hermance et al., 2005; Meylan et al., 2004). Fur-
thermore, RIP1 is necessary for DNA-damage-induced activa-
tion of IKK via the PIDDosome (Hur et al., 2003; Janssens et 
al., 2005). Interestingly, RIP1 is not required for activation of the 
noncanonical pathway through CD40 or LTβR (Vivarelli et al., 
2004). Therefore, RIP1 appears to be required for activation of 
a subset of canonical, but not noncanonical, NF-κB signaling 
pathways. Regulation of NIK directly by TRAFs and the binding 
of NEMO by RIP1 are consistent with RIP proteins not being 
involved in noncanonical signaling.
In addition to RIP1, RIP2 has been widely implicated in sig-
naling pathways to NF-κB. RIP2 contains a C-terminal CARD, 
a homotypic interaction motif that allows RIP2 to function in a 
distinct set of NF-κB signaling pathways. The antigen receptor 
signaling pathways have shed significant light on the role of 
CARDs in the activation of NF-κB. Both BCL10 and CARD11 
(CARMA1) are CARD-containing proteins that are crucial for 
IKK activation downstream of either the T cell or B cell antigen 
receptors. The most notable feature of the BCL10, CARD11, 
MALT1 (CBM) complex is its induced oligomerization follow-
ing signaling, which is thought to be a key event in IKK activa-
tion downstream of these CARD-containing adaptor proteins 
(Schulze-Luehrmann and Ghosh, 2006). RIP2 seems to be 
required for BCL10-mediated NF-κB signaling (Ruefli-Brasse 
et al., 2004). Whether antigen receptors also act through TRAF 
family proteins to signal to NF-κB has yet to be shown conclu-
sively. TRAF6, perhaps partially complemented by TRAF2, is 
the most likely TRAF downstream of the CBM complex; how-
ever this remains controversial (Scheidereit, 2006; Schulze-
Luehrmann and Ghosh, 2006).
Members of the NOD-LRR family of intracellular pattern 
recognition receptors are CARD-containing proteins that can 
activate IKKβ via RIP2. RIP2 binds to NEMO and is believed 
to directly mediate activation of the IKK complex by proximi-
ty-induced mechanisms (Inohara et al., 2000). However, more 
recent results suggest that RIP2 acts with TAK1 and TRAFs to 
induce NEMO ubiquitination and downstream signaling path-
ways (Abbott et al., 2007; Kim et al., 2008). Similar to RIP1, the 
kinase activity of RIP2 does not appear to be required, and 
RIP2 is also ubiquitinated through the action of Ubc13/TRAF6 
(Hasegawa et al., 2007; Park et al., 2007; Yang et al., 2007). The 
role of TRAF proteins has not been clearly delineated in NOD-
LRR-mediated NF-κB activation. It is possible that confusion 
on this issue may be the result of different TRAF family mem-
bers, TRAF2, 5, and 6, serving redundant or compensatory 
functions, similar to the situation seen for TRAF2 and TRAF5 in 
TNFR1 signaling (Abbott et al., 2007; Hasegawa et al., 2007).
Thus, RIP proteins, RIP1 as a DD to NEMO adaptor and RIP2 
as a CARD to NEMO adaptor, seem to play an analogous role 
in several canonical NF-κB activation pathways. RIP proteins 
recruit the IKK complex through binding to NEMO and may 
mediate activation of the complex through direct oligomeriza-
tion or ubiquitin-dependent mechanisms. Whether TRAF pro-
teins directly contribute to this RIP function through ubiquitina-
tion or do so indirectly is unclear, although the field may have 
moved significantly closer with the identification of the key role 
of TAK1 in most RIP-dependent NF-κB pathways.
TAK1/NIK—IKK Kinases?
Signaling to IKK downstream of RIPs and TRAFs depends on 
several kinases that have been implicated in NF-κB signaling 
pathways. In the case of canonical NF-κB pathways this role 
is largely fulfilled by TAK1 (TGFβ-activated kinase-1) (Sato et 
al., 2005; Shim et al., 2005). In noncanonical pathways NIK is 
instead required for IKKα activation and p100 phosphorylation 
(Senftleben et al., 2001; Xiao et al., 2001). Whether NIK and 
TAK1 function analogously to one another, that is as putative 
IKK kinases (IKK-Ks), is a matter of some debate. Despite the 
clear requirement for TAK1 in multiple signaling pathways to 
IKK, the mechanism of action of TAK1 in signaling to NF-κB 
remains unclear. First, genetic ablation of TAK1 reveals vari-
able NF-κB activation deficiencies in different canonical sig-naling pathways. TNFR1 signaling to NF-κB appears com-
pletely abolished, while the effect on antigen receptor signaling 
is more controversial (Liu et al., 2006; Sato et al., 2005; Wan 
et al., 2006). Second, whether TAK1 directly serves as an 
IKK-K or mediates activation through an intermediary kinase, 
MEKK3 for example, is not yet clear (Blonska et al., 2005; Li 
et al., 2006a). Third, even though the pathways triggered by 
LTβR lead to IKK through many of the same signaling inter-
mediates, this pathway does not depend on TAK1 (Shim et al., 
2005). Instead it seems that TAK1 generally functions in path-
ways that also require RIP for the activation of IKK. Indeed, RIP 
may be responsible for the recruitment of TAK1 (Blonska et al., 
2005). TAK1 has been implicated in both antigen receptor and 
NOD signaling pathways, neither of which has yet been shown 
conclusively to depend on TRAF proteins, although there are 
indications that this is likely to be the case (Abbott et al., 2007; 
Hasegawa et al., 2007; Sun et al., 2004). Alternatively, it may be 
that some pathways that signal independently of RIPs, which 
to date includes mainly noncanonical pathways, may activate 
IKK without TAK1. Conversely, NIK can activate the noncanoni-
cal pathway in the absence of RIP proteins.
NIK directly phosphorylates and activates IKKα and this 
model is supported by analyses of NIK−/− and aly/aly mice, which 
bear an inactivating point mutation in the NIK kinase (Hacker 
and Karin, 2006). Regulation of NIK is regulated by the com-
bined action of TRAF proteins, as discussed above. In addition 
to TRAF3, cIAP1 and cIAP2 have been implicated as E3 ligases 
responsible for regulating constitutive NIK levels (Petersen et 
al., 2007; Varfolomeev et al., 2007; Vince et al., 2007). Degrada-
tion of cIAP downstream of noncanonical stimuli may function, 
like degradation of TRAF3, in leading to the accumulation of 
NIK and IKKα activation (Varfolomeev et al., 2007). However, 
the mechanism of cIAP regulation following receptor ligation 
needs to be further characterized.
In summary, a few common signaling components mediate 
activation of IKK under most circumstances. In the noncanoni-
cal pathway, TRAF and NIK are sufficient to activate IKKα in a 
NEMO-independent manner. However, the canonical pathway 
appears more complex. Generally canonical signaling relies 
on both TRAF and RIP proteins, as well as the kinase TAK1, 
although in certain pathways other proteins, e.g., IRAK1, may 
function analogously to RIP. It seems that the key to this dif-
ference is likely to lie in binding of RIP, or analogous proteins, 
to NEMO, as both of these components may be universally 
required for canonical NF-κB activation. Whether this inter-
action allows TAK1 or another kinase to phosphorylate IKK or 
promotes IKK transautophosphorylation remains a matter of 
continuing debate. If there is no IKK-K in canonical pathways, 
however, then the exact function of TAK1 in IKK activation 
remains to be discovered.
Organization and Activation of the IKK Complex
Although exceptions have been reported, it is generally 
accepted that activation of NF-κB requires activation of either 
IKKα or IKKβ. It therefore follows that understanding the regu-
lation of IKK activity is central to understanding the activation 
of NF-κB. Despite the significance of IKK, major gaps remain 
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However, several recent advances suggest that the field is on 
the verge of significant breakthrough into understanding the 
mechanism of IKK activation.
The IκB kinase was first purified as a basally active, high-
molecular-weight complex capable of phosphorylating ser-
ines 32 and 36 of IκBα (Chen et al., 1996). A stimulus-depen-
dent kinase activity was subsequently identified by several 
groups and found to be composed of the two catalytic kinase 
subunits, IKKα (IKK1) and IKKβ (IKK2), and a regulatory sub-
unit NEMO (IKKγ) (DiDonato et al., 1997; Mercurio et al., 1997; 
Rothwarf et al., 1998; Woronicz et al., 1997; Yamaoka et al., 
1998; Zandi et al., 1997; Regnier et al., 1997). IKKα and IKKβ, 
along with IKKi (IKKε) and TBK1, comprise the IKK family of 
proteins. IKKα and IKKβ share 52% overall sequence iden-
tity, with a greater degree of similarity in the catalytic domain 
(65%). NEMO is a 48 kDa protein that is not related to IKKα 
and IKKβ and contains a C-terminal Zn finger-like domain, 
a leucine zipper, and N-terminal and C-terminal coiled-coil 
domains (Figure 2).
Targeted disruption of each of the IKK genes as well as trans-
genic and conditional knockout animals have been generated 
and extensively analyzed and reviewed recently (Gerondakis et 
al., 2006; Pasparakis et al., 2006). Initially the similarity between 
the IKKβ knockout and p65 knockout phenotypes argued for 
a central role for IKKβ in activation of p65 dimers via IκBα 
phosphorylation. Mice deficient in IKKα survive embryonic 
development but die perinatally due to multiple morphological 
defects, in particular aborted epidermal and skeletal develop-
ment. While initially it appeared that IKKα was dispensable for 
classical NF-κB activation, subsequent reports revealed the 
requirement for IKKα in multiple noncanonical NF-κB signal-
ing pathways and perhaps some canonical signaling pathways 
as well (Solt et al., 2007; Takaesu et al., 2003). Furthermore, 
as discussed below, while not required for IκBα degradation 
in all pathways, IKKα likely plays an important role in NF-κB-
dependent gene expression in canonical signaling pathways. 
NEMO is required for signaling in all canonical NF-κB pathways 
and NEMO-deficient mice also die embryonically of massive 
hepatocyte apoptosis. NEMO-deficient cells exhibit a more 
severe and broader loss of NF-κB activation than do IKKβ 
knockout cells, demonstrating that some canonical pathways 
are intact in the absence of IKKβ (Schmidt-Supprian et al., 
2000; Solt et al., 2007). Therefore, it is more appropriate to cat-
egorize NF-κB pathways as canonical or noncanonical based 
on the requirement for NEMO or on the specific IκB protein that 
is phosphorylated and degraded/processed, e.g., IκBα, IκBβ, 
and IκBε for canonical and p100 for noncanonical, rather than 
on the requirement for IKKα or IKKβ.
The IKK Complex
Multiple lines of evidence point toward an IKK kinase complex 
that is composed of only IKKα, IKKβ, and NEMO. Recombinant 
NEMO plus either IKKα or IKKβ assembles into a complex with 
an apparent molecular weight that is similar to the purified com-
plex (Krappmann et al., 2000; Miller and Zandi, 2001). NEMO 
has a large Stoke’s radius in vitro and consequently NEMO 
trimers with a predicted molecular weight of 150,000 elute at 
an apparent molecular weight of 550 kDa upon gel filtration 
(Agou et al., 2004). However, it remains to be seen whether 350 Cell 132, February 8, 2008 ©2008 Elsevier Inc.NEMO assembled with IKK in vivo exhibits a similar discrep-
ancy between predicted and actual molecular weights. Alter-
natively, this discrepancy may simply reflect an IKKα/β/NEMO 
complex of higher-order stoichiometry. Recombinant NEMO 
and IKKβ appear to associate in a 2:2 molar ratio and the mini-
mum interaction domains form a dimer of dimers (tetramer) that 
can further assemble into octamers and dodecamers (Drew 
et al., 2007). These higher-ordered assemblies easily reach 
the molecular weight of the endogenous complex. Therefore, 
additional subunits are most likely not present in the active IKK 
complex, nor are they required to explain the large apparent 
molecular weight of the complex. Instead, based on existing 
biochemical evidence, and our own unpublished observations, 
it would appear that proteins reported to associate with the IKK 
complex do so in a transient and/or substoichiometric man-
ner and do not reflect additional bona fide components of the 
IKK complex. Therefore, we confine our discussion of the IKK 
complex largely to the core IKK components IKKα, IKKβ, and 
NEMO.
IKKα and IKKβ dimerize through the leucine zipper domain, 
which is also required for kinase activity (Mercurio et al., 1997; 
Woronicz et al., 1997; Zandi et al., 1997). It appears that IKKα 
and IKKβ preferentially form heterodimers in vivo, and in vitro 
studies indicate that IKKα/IKKβ heterodimers have higher cat-
alytic efficiency than either homodimer (Huynh et al., 2000). 
While both IKKα and IKKβ homodimerize in cells lacking IKKβ 
or IKKα, respectively, there is little evidence that homodimers 
form under normal conditions. The exceptions are descriptions 
of IKKβ/IKKβ/NEMO complexes in T cells and an IKKβ-only 
complex in TNFα-stimulated HeLa cells (Khoshnan et al., 1999; 
Mercurio et al., 1999). Interestingly, T cells have been reported 
to express truncated IKKα isoforms lacking the leucine zipper 
that would presumably promote IKKβ homodimer formation 
(McKenzie et al., 2000). In addition, despite the lack of hard 
evidence, it is still commonly believed that IKKα homodim-
ers, which are not bound to NEMO, exist in vivo because the 
noncanonical pathway can function in the absence of IKKβ or 
NEMO (Senftleben et al., 2001).
IKKα and IKKβ bind NEMO through the C-terminal hexa-
peptide NEMO-binding domain (NBD) (Leu-Asp-Trp-Ser-Trp-
Leu) (May et al., 2000, 2002) (Figure 2). NEMO binding to IKKs 
requires at a minimum residues 47–80, located within the first 
coiled-coil motif (Drew et al., 2007; Marienfeld et al., 2006; May 
et al., 2002). Competition experiments and biophysical analy-
ses using the NBD peptide indicate that IKKβ binds to NEMO 
with considerably higher affinity than IKKα (May et al., 2002 
and unpublished data). Furthermore, IKKα is less sensitive to 
mutation of two residues within the NBD (Asp749 and Trp742) 
that abolish IKKβ binding to NEMO, indicating that the binding 
of IKKα is less stringent. Differences in NEMO-binding affinity 
may be crucial to understanding differences in IKKα and IKKβ 
function in vivo because swapping the IKKα and IKKβ C termini 
produces an IKKα that exhibits IKKβ-like behavior (Kwak et al., 
2000). Furthermore, while IKKα lacking the leucine zipper, HLH 
domain and NBD is active upon overexpression, the same dele-
tions abrogate IKKβ activity (McKenzie et al., 2000). Therefore 
the C-terminal region of IKK, which mediates both NEMO bind-
ing and dimerization, affects kinase activity and selection.
Although the core IKK complex most likely consists of only 
IKKα/IKKβ/NEMO, there are two well-characterized and highly 
cited interactions that deserve some discussion. The first is 
the kinase chaperone HSP-90/Cdc37 that has been reported 
to constitutively associate with the IKK complex. The HSP-90 
inhibitor geldanamycin has also been shown to inhibit activa-
tion of IKK by TNF-α (Chen et al., 2002a). However, HSP-90 
also associates with multiple kinases that are involved in the 
NF-κB pathway (Ghosh and Karin, 2002). It has recently been 
shown that rather than being an IKK complex component per 
se, HSP-90 is instead recruited by Cdc37 to IKK where it func-
tions as a chaperone during assembly of the IKK complex, or 
during its reconstitution following signaling (Hinz et al., 2007). 
The second interacting protein that requires mentioning is 
ELKS, which has been proposed to be a regulatory component 
of the IKK complex in addition to NEMO (Ducut Sigala et al., 
2004). While RNAi knockdown studies support a role for ELKS 
in IKK activation and immunodepletion analyses indicate that 
ELKS is a stoichiometric component of the IKK complex, the 
importance of ELKS in IKK function has not been established 
genetically, and its regulation remains to be characterized in 
detail (Ducut Sigala et al., 2004).
Activation of IKK
Activation of the IKK complex requires phosphorylation of T 
loop serines of at least one of the IKK subunits. However, the 
mechanism through which this phosphorylation occurs remains 
unclear. Active IKKβ is phosphorylated on two serines, Ser177 
and Ser181, within the activation loop of the kinase domain, 
and IKKα is similarly phosphorylated on activation loop serine 
residues 176 and 180. Mutation of the activation loop serines to 
glutamic acid yields constitutively active IKK, while mutation to 
alanines abrogates signal responsiveness (Hacker and Karin, 
2006). How enzymatic activity is regulated by phosphoryla-
tion of these serines can be surmised from comparison with 
other kinases but ultimately awaits a crystal structure of the 
IKK complex that, to date, has been elusive. Regardless of the 
precise conformational change induced by these key phos-
phorylation events, the fundamental question remains whether 
IKK phosphorylation occurs by transautophosphorylation or 
through phosphorylation by an upstream kinase (IKK-K).
There are several lines of evidence that can be used to sup-
port either IKK-K or transautophosphorylation mechanisms: in 
fact, to some extent, the same evidence can be used to sup-
port both models. One common element in IKK activation is 
the requirement for TRAF family members and the induced 
oligomerization of TRAFs following signaling. This commonal-
ity underscores the importance of the assembly of complex 
signalosomes for the activation of IKK. Further, oligomerization 
is universal even where TRAFs may not be required. In AgR 
signaling the CBM complex also assembles into a higher-order 
oligomer following signaling (Schulze-Luehrmann and Ghosh, 
2006). Thus it appears that canonical NF-κB signaling path-
ways all lead to the assembly of large clusters of signaling com-
ponents immediately upstream of IKK. Oligomerization of RIP 
proteins, RIP1 downstream of TRAFs and RIP2 downstream 
of CARD-containing adapters, may also provide a scaffold for 
IKK complex oligomerization (Inohara et al., 2000). Assembly 
of these signaling complexes suggests that IKK activation might occur through an induced proximity model of transau-
tophosphorylation; however it is also possible that these same 
signalosomes could just as easily serve to position IKK near 
an IKK-K.
The C-terminal region of NEMO mediates activation of IKK 
and interaction with upstream signaling adapters, whereas it 
is the NEMO N terminus that is responsible for interaction with 
IKKs (Makris et al., 2002; Rothwarf et al., 1998). Inducible oli-
gomerization of NEMO mediated by RIP1 has been speculated 
to activate IKK, and artificially enforced NEMO oligomerization 
leading to IKK activation further supports this hypothesis (Ino-
hara et al., 2000; Poyet et al., 2000). As discussed above, NEMO 
can form tetramers in vitro and also is reported to oligomerize 
in vivo, although the stoichiometry of endogenous NEMO is 
debatable (Agou et al., 2004; Drew et al., 2007; Tegethoff et 
al., 2003). Nevertheless, mutation of sequences required for 
the observed oligomerization results in a loss of IKK activity, 
as does overexpression of the oligomerization domain alone 
(Agou et al., 2004; Tegethoff et al., 2003). Without structural 
information it is difficult to know how NEMO oligomerization 
might bring about IKK activation; however, three recent publi-
cations may shed some light on the mechanism of IKK activa-
tion (Marienfeld et al., 2006; Palkowitsch et al., 2008; Schomer-
Miller et al., 2006).
It is possible that oligomerization of NEMO is required for 
transautophosphorylation of the IKK T loop serines or even to 
expose T loop serines to an IKK-K. Indeed, the kinase activ-
ity of wild-type IKKβ expressed in yeast is increased by coex-
pression of NEMO; however, the activity of IKK in which the T 
loop serines have been mutated to glutamic acid is high and 
unchanged by coexpression of NEMO (Schomer-Miller et al., 
2006). Therefore, augmentation of IKK kinase activity by NEMO 
most likely occurs through facilitation of IKK T loop phospho-
rylation. The ability to recreate this process in yeast strongly 
suggests that transautophosphorylation occurs as a result of 
the formation of spontaneous higher-order structures of NEMO 
and IKK that display apparent molecular weights similar to that 
of activated IKK (Miller and Zandi, 2001). Transautophospho-
rylation is also consistent with the known dependence on IKK 
dimerization for IKK activation. Abrogation of both homo- and 
heterodimer formation by deletion or mutation of the IKK leu-
cine zipper domain also blocks activation of overexpressed 
IKKs (McKenzie et al., 2000; Tang et al., 2003; Zandi et al., 
1997). However, kinase activity can be restored by forced oli-
gomerization of IKK using an unrelated dimerization interface 
(Tang et al., 2003). In addition, kinase-active IKKβ is capable 
of transautophosphorylation of kinase-dead IKKβ, and this 
activation requires leucine zipper-dependent dimerization or 
artificially enforced oligomerization (Tang et al., 2003). Intrigu-
ingly, phosphorylation of the IKK NBD serine residues (Ser740) 
inhibits IKK activity and prevents augmentation of recombi-
nant IKK activity by coexpression with NEMO (May et al., 2002; 
Schomer-Miller et al., 2006). IKK lacking the NBD, on the other 
hand, exhibits constitutive activity in the absence of stimula-
tion (May et al., 2002). Because IKK containing Ser740 mutated 
to Ala continues to interact with NEMO, these data suggest 
that the nature of the NBD/NEMO interaction is important for 
NEMO-mediated IKK activation (May et al., 2002; Schomer-Cell 132, February 8, 2008 ©2008 Elsevier Inc. 351
Miller et al., 2006). In addition to undergoing stimulus-induced 
oligomerization, NEMO constitutively forms stable dimers, and 
both dimerization and IKK binding are independently required 
for activation of NF-κB (Marienfeld et al., 2006). While over-
expression of the NEMO dimerization and IKK interaction 
domain alone (aa 1–197) can activate IKK, similar to the effect 
of a C-terminal portion containing the minimal oligomerization 
domain (MOD) (179–419), neither constructs facilitate IKK acti-
vation in the absence of full-length (FL) NEMO (Marienfeld et 
al., 2006).
However this interaction may be an important mechanism of 
negative feedback regulation. NEMO becomes phosphorylated 
at Ser68 within the IKK-binding domain following stimulation. 
This phosphorylation occurs in a stimulus-dependent manner 
and induces the disruption of NEMO dimers and interaction 
between IKK and NEMO, thereby terminating signaling (Palkow-
itsch et al., 2008). This separation of IKK and NEMO is further 
augmented by phosphorylation of the IKK NBD (Palkowitsch 
et al., 2008). These induced conformational changes may then 
allow recognition by the HSP-90 kinase chaperone complex or 
proposed IKK complex phosphatases, resulting in reconstitution 
of a signaling-competent IKK complex through either HSP-90 
chaperone function or dephosphorylation of NEMO at Ser68.
Based on these findings the following model for IKK activation can 
be proposed (Figure 3). In the resting state, in (NEMO2IKKα1IKKβ1)2 
complexes, the IKKs are held inactive through their interaction 
with NEMO. Upon stimulation, NEMO binds to a RIP protein, per-
haps in an ubiquitin-dependent manner, which induces a confor-
mational change that allows transautophosphorylation or IKK-K 
phosphorylation of the IKK T loop serine 
residues. Active IKK then phosphorylates 
both downstream substrates such as 
IκBs, as well as Ser740 in IKKβ and Ser68 
in NEMO. These phosphorylation events 
open up the complex allowing access to 
phosphatases that by dephosphorylating 
IKK T loop serines cause termination of 
kinase activity. The chaperone activity of 
HSP-90 and dephosphorylation of Ser740 
of IKKβ may be required to overcome the 
high affinity of the IKKβ NBD-NEMO interaction. The lower affinity 
of the IKKα NBD for NEMO may allow active IKKα to escape from 
Ser68-phosphorylated NEMO/IKK complexes and further aug-
ment NF-κB activation through the phosphorylation of additional 
downstream targets.
Oligomerization appears to be a shared theme in signal-
ing to NF-κB. There have been multiple reports describing 
oligomerization of TRAF proteins in multiple pathways that 
signal to NF-κB. RIP proteins, which are essential for canoni-
cal pathways, also form some degree of higher-order struc-
tures most likely as a result of aggregation of receptor and/
or adaptor complexes. Furthermore, in certain pathways, such 
as NOD-LRRs, receptor and RIP oligomerization is particularly 
well characterized (Inohara and Nunez, 2003). RIP interaction 
with NEMO would thus be predicted to directly induce cluster-
ing of IKK complexes. RIP also becomes rapidly ubiquitinated 
following TNFα stimulation, and it has been proposed that it 
is through this posttranslational modification that RIP1 binds 
to NEMO (Wu et al., 2006). If this is the case then a single RIP 
molecule or, for that matter, ubiquitinated TRAF, IRAK-1, or 
MALT1 could provide an oligomeric ubiquitin scaffold medi-
ating oligomerization or conformational changes in the IKK 
complex. Analysis of the interaction has been complicated by 
sequence overlap between the NEMO oligomerization domain 
and the NEMO K63-ubiquitin-binding domain (UBD). In addi-
tion to RIP, NEMO is also ubiquitinated in multiple NF-κB 
pathways. K63-linked NEMO ubiquitination has perhaps been 
demonstrated most clearly in AgR signaling, where it has been 
shown that mutation of a single lysine acceptor site prevents 
Figure 3. A Putative Model for IKK Activation
In the resting state, IKKα and IKKβ bind to NEMO 
such that activation is prevented. Conformational 
changes in the IKK complex induced by binding of 
NEMO to RIP, and/or ubiquitination of NEMO, lead 
to the exposure of IKK kinase domain and T loop 
serines and consequent transautophosphorylation 
or phosphorylation by an IKK-K such as TAK1. The 
active IKK then phosphorylates downstream sub-
strates, including serine 740 within the IKK NBD 
and serine 68 in NEMO. NEMO phosphorylation re-
sults in the separation of stable NEMO dimers and 
NEMO binding to IKK. Dephosphorylation of the 
IKK T loop results in kinase inactivation, whereas 
phosphorylation of the IKK NBD and NEMO ser-
ine 68 prevents reactivation of the kinase. Cdc37/
HSP-90-mediated chaperone activity and PP2A 
and PP2Cβ phosphatase activity may then medi-
ate regeneration of the IKK complex.352 Cell 132, February 8, 2008 ©2008 Elsevier Inc.
NEMO ubiquitination, although this change did not completely 
inhibit NF-κB activation (Zhou et al., 2004). NEMO ubiquitina-
tion has also been shown to be important in the DNA-damage 
response, raising the possibility that this phenomenon may be 
linked to the TRAF independence of these pathways.
While it is clear that a variety of pathways require oligomer-
ization and/or ubiquitination of upstream signaling components 
for IKK activation, these observations are not inconsistent with 
the additional requirement for IKK-Ks. These two mechanisms 
may operate separately in independent NF-κB pathways. In 
fact the necessity for NIK in activation of IKKα is well estab-
lished and, as discussed above, appears to be independent 
of RIP proteins. Therefore in noncanonical signaling pathways, 
where RIP-mediated oligomerization of NEMO does not occur, 
IKKα activation may be mediated through direct T loop phos-
phorylation by NIK. The lower affinity of IKKα for NEMO may 
facilitate NIK access to the IKKα T loop but not to that of IKKβ, 
either as part of IKKα-only complexes or due to conformational 
differences between IKKα and IKKβ when bound to NEMO. As 
a result IKKα activation can be independent of RIP-mediated 
NEMO oligomerization, as IKKα is not regulated by NEMO in 
the same manner as IKKβ.
Activation of IKK activity is a transient event, and therefore 
IKK must also be subject to negative feedback regulation. 
There are numerous negative feedback mechanisms that affect 
upstream signaling components, most notably the deubiquit-
inases A20 and CYLD, which have been reviewed elsewhere 
recently (Chen et al., 2006; Hacker and Karin, 2006). How-
ever, there is also evidence for IKK intrinsic negative feedback 
mechanisms (Figure 3). Phosphorylation of the C-terminal NBD 
of IKK may be an important component of such a negative 
feedback loop (May et al., 2002; Schomer-Miller et al., 2006). 
Consistent with this hypothesis, the protein phosphatase 2A 
(PP2A) has been shown to associate with IKK and potentiate 
IKK activation in cells (Kray et al., 2005; Li et al., 2006b). Con-
versely, in vitro PP2A blocks IKK activity by removing T loop 
phosphorylation (DiDonato et al., 1997). In addition, structural 
changes induced by NEMO Ser68 and IKK NBD phosphoryla-
tion may allow dephosphorylation of the activation loop serines 
in IKKs as well as N-terminal phosphorylation sites in NEMO 
by PP2A or PP2Cβ (Kray et al., 2005; Palkowitsch et al., 2008; 
Prajapati et al., 2004).
IKK Substrates
When overexpressed or assayed in vitro, IKKα and IKKβ are 
both able to phosphorylate multiple members of the IκB family, 
although with differing specificities. For example, both IKKα 
and IKKβ phosphorylate IκBα at Ser32 and Ser36 and IκBβ 
at Ser19 and Ser23; however, IKKα is less efficient and con-
sequently cannot complement IKKβ knockout cells (Hacker 
and Karin, 2006; Hayden and Ghosh, 2004). Furthermore, both 
IKKα and IKKβ prefer IκBα to IκBβ, which is consistent with the 
difference in IκBα and β degradation kinetics—IκBβ degrada-
tion is significantly slower than IκBα in most canonical path-
ways in which both are degraded (Wu and Ghosh, 2003). IκBα 
bound to NF-κB is thought to be a preferred substrate to free 
IκBα (Zandi et al., 1998). This might diminish the degradation 
of newly synthesized IκBα, thereby allowing this key negative 
feedback loop to function properly. Phosphorylation of p100 by IKKα occurs at Ser872 as well as at several N-terminal serine 
residues. While serines are also required for p100 processing, 
it is thought that these residues primarily function as a dock-
ing site for NIK and IKKα (Liang et al., 2006; Xiao et al., 2004). 
Phosphorylation of other IκB family members is less well 
characterized, and this is an area where additional research 
is clearly needed. Finally, IKKs have also been reported to 
phosphorylate many other proteins besides the IκB family. In 
particular, the role of IKKα in regulating NF-κB transcriptional 
responses, by targeting transcriptional cofactors, NF-κB itself, 
and other targets is discussed in the context of transcriptional 
regulation.
Expanding Functions for IκBs
Our understanding of how IκB proteins function has undergone 
significant change. In addition to being inhibitors of NF-κB func-
tion, both by preventing nuclear localization and DNA binding, 
more varied functions for IκBs have now been described. Most 
importantly, it now appears that multiple IκB family proteins 
positively regulate transcription by acting as coactivators.
The “Typical” IκBs—IκBα, IκBε, and IκBβ
IκBα is the prototypical member of the IκB family exhibiting 
the defining traits that characterize IκB proteins. The canoni-
cal p65/p50 heterodimer is largely, though not exclusively, 
found bound to IκBα, and rapid signal-induced IκBα protea-
somal degradation is required for nuclear import and DNA 
binding by NF-κB p50/p65. The nuclear NF-κB drives IκBα 
expression generating a negative feedback loop. Therefore, 
in the absence of IκBα the termination of NF-κB activation in 
response to canonical stimuli such as TNF-α is significantly 
delayed (Gerondakis et al., 2006; Pasparakis et al., 2006). The 
duration of the NF-κB response relies heavily on the kinetics of 
the feedback pathway and, for example, the kinetics of NF-κB 
inactivation can be grossly restored by placing a different IκB, 
e.g., IκBβ, under the control of the IκBα promoter (Cheng et 
al., 1998).
IκBα, IκBβ, and IκBε are considered to function as traditional 
IκB proteins: that is they sequester NF-κB dimers away from κB 
elements thus inhibiting transcription. Although IκBβ knocked 
into the genome replacing IκBα can serve analogously to IκBα, 
there are enough differences between these inhibitors such that 
it is unlikely that IκBα and IκBβ are completely interchangeable. 
Indeed, analyses of NF-κB responses in MEFs lacking one, 
two, or all three IκB proteins demonstrate that they have unique 
functions, even within a given signaling pathway. The functional 
characteristics of IκBα, IκBβ, and IκBε are most likely a result of 
temporal differences in their degradation and resynthesis (Hoff-
mann et al., 2002). More recently, using cells deficient in all three 
traditional IκB proteins, it has been shown that the long-standing 
model of cytoplasmic sequestration by IκBs is only partially true 
(Tergaonkar et al., 2005). In particular, cells that lack all three 
subunits show relatively normal nuclear/cytpolasmic p65 distri-
bution but significantly increased basal NF-κB-dependent gene 
expression, suggesting that regulation of NF-κB transcriptional 
activity by IκBs is partly independent of cytoplasmic sequestra-
tion. This work also definitively confirmed that stimulus-induced 
activation of canonical NF-κB requires the three typical IκB pro-
teins (Tergaonkar et al., 2005).Cell 132, February 8, 2008 ©2008 Elsevier Inc. 353
Like IκBα, IκBε is degraded in an IKK-dependent manner 
and its expression is upregulated by NF-κB. However, IκBε 
degradation and resynthesis occur with considerably delayed 
kinetics compared to that of IκBα. The difference in the kinet-
ics of IκBε and IκBα degradation has profound effects on the 
nature of the transcriptional response to TNF (Kearns et al., 
2006). IκBε is primarily expressed in hematopoietic cells, and 
loss of IκBε results in selective defects in hematopoietic lin-
eages, although it appears that IκBε loss is largely compen-
sated for by IκBα (Goudeau et al., 2003; Samson et al., 2004). 
The temporal and cell type-specific degradation of IκBε sup-
ports the hypothesis that different IκBs can play unique func-
tions in NF-κB responses.
The unique function of IκBβ, however, has been difficult to 
define. Although IκBβ, like IκBε, undergoes slow degradation 
and resynthesis, deletion of IκBβ does not dramatically affect 
the kinetics of the NF-κB responses as seen in the deletion of 
IκBα or ε (Hoffmann et al., 2002; Kearns et al., 2006). However, 
both the nuclear/cytoplasmic localization and posttranslational 
modification of IκBβ seem to be unique, and IκBβ is capable 
of associating with NF-κB dimers that are bound to DNA (Suy-
ang et al., 1996; Thompson et al., 1995). These data suggest 
that IκBβ might function to regulate NF-κB dimers bound to κB 
sites in the nucleus.
The Precursor IκBs—p100 and p105
The IκB/NF-κB precursor protein p105 undergoes process-
ing via the proteasome to yield p50. Multiple reports have 
demonstrated that IKKβ-dependent phosphorylation of the 
C-terminal region of p105 at Ser923 and Ser927 (Ser933 in 
human p105) leads to complete degradation of the protein 
analogous to IκBα (Hayden and Ghosh, 2004; Perkins, 2006). It 
was recently demonstrated that SCFβTrCP is not responsible for 
signal-induced processing of p105, and it has been suggested 
that this event is independent of ubiquitination (Cohen et al., 
2004). Constitutive processing of p105 to p50 has been shown 
to occur cotranslationally, although a recent analysis demon-
strates that processing of p105 can occur posttranslationally 
(Lin et al., 1998, 2000; Moorthy et al., 2006). Normal process-
ing of p105 to p50 in an E1 Ub-activating enzyme-deficient 
cell line, complemented by in vitro analysis, strongly suggests 
that p105 processing can occur via the 20S proteasome, inde-
pendent of ubiquitination, and in a manner that is inconsistent 
with cotranslational processing (Moorthy et al., 2006). When 
p105 is bound to NF-κB complexes it appears that process-
ing is inhibited and induced degradation is favored (Cohen et 
al., 2001; Harhaj et al., 1996). Thus unprocessed p105 acts as 
an IκB protein that binds NF-κB dimers and can be inducibly 
degraded upon IKK activation. In addition, the 3′ end of the 
p105 gene also encodes an independently regulated tran-
script, IκBγ, which shows separate tissue distribution and may 
function as an independent IκB protein in murine cells (Hayden 
and Ghosh, 2004).
Processing of p100 requires IKKα and is predominantly stim-
ulus dependent (Senftleben et al., 2001). NIK is required for the 
activation of IKKα and may also be necessary for phosphory-
lation of p100 by active IKKα (Xiao et al., 2001, 2004). Phos-
phorylation of p100 at serines 866, 870, and 872 (Ser865, 869, 
and 871 in human p100) leads to the recruitment of SCFβTrCP, 354 Cell 132, February 8, 2008 ©2008 Elsevier Inc.polyubiquitination of Lys855 in a region with sequence homol-
ogy to Lys22 of IκBα, and subsequent degradation or process-
ing to p52 (Amir et al., 2004; Fong et al., 2002; Liang et al., 
2006). However, it has been suggested that IKKα, although 
required, may not be responsible for phosphorylation of these 
key serine residues (Liang et al., 2006; Xiao et al., 2004). Con-
stitutive processing of p100 to p52, which occurs at a low level 
in a cell type-specific manner, is also dependent on IKKα and 
NIK (Qing and Xiao, 2005; Xiao et al., 2004). Regulation of RelB 
by p100 is especially crucial because RelB-containing dim-
ers only associate with p100, and it has been suggested that 
they require p100 binding for stabilization (Solan et al., 2002). 
Because p100 undergoes constitutive processing in certain tis-
sues, RelB/p52 heterodimers may exhibit constitutive activa-
tion and RelB-deficient mice have decreased baseline NF-κB 
activity in the thymus and spleen (Gerondakis et al., 2006; 
Pasparakis et al., 2006). While RelB is regulated exclusively by 
p100, p100 itself can act more broadly. In addition to IκBα/β/ε, 
p100 can also act as a traditional IκB regulating p65-containing 
complexes downstream of IKKα (Basak et al., 2007). Likewise 
it has been shown that in T cells p100 also limits p65-mediated 
NF-κB activity in a negative feedback loop set up following T 
cell activation (Ishimaru et al., 2006). Consequently p100 can 
act in the induction of canonical and noncanonical NF-κB 
complexes as well as in the positive and negative regulation 
of constitutive NF-κB activity. Therefore, p100 displays several 
key properties that are likely to be important for NF-κB regula-
tion: (1) selective regulation of specific NF-κB complexes such 
that in its absence a subset of inducible NF-κB responses, i.e., 
RelB-dependent gene expression, is lost; (2) selective function 
of IκB subunits downstream of specific signaling pathways; (3) 
finally, regulation of basal activity of specific NF-κB dimers.
The “Atypical” IκBs—IκBζ and Bcl-3
IκBζ and Bcl-3 are the remaining two IκB family members, and 
appear to regulate NF-κB signaling by a distinct mechanism. 
Bcl-3 is unique in that in contains a TAD. Bcl-3 is found in the 
nucleus associated with p50- and p52-containing homo- and 
heterodimers. The mechanism of action of Bcl-3 is still not 
completely understood. Bcl-3 may mediate release of tran-
scriptional repression by removing p50 homodimers from κB 
sites, thus acting as a traditional IκB but mediating activation 
by acting on repressive NF-κB dimers and allowing p65:p50 or 
other TAD-containing dimers access to κB elements (Hayden 
and Ghosh, 2004; Perkins, 2006). Alternatively, Bcl-3 may also 
stabilize repressive p50 homodimers and inhibit NF-κB activa-
tion by preventing the access of TAD-containing dimers to κB 
sites (Carmody et al., 2007). As a result, the induction of Bcl-3 
expression inhibits subsequent NF-κB activation and may con-
tribute to LPS tolerance in macrophages. Conversely, in the 
case of p52 homodimers it is thought that Bcl-3 confers tran-
scriptional potential in an inducible manner (Bours et al., 1993). 
Cyclin D1 is a Bcl-3-regulated gene that is of particular inter-
est owing to its role in cell proliferation and cancer (Rocha et 
al., 2003; Westerheide et al., 2001). It has been demonstrated 
recently that the deubiquitinase CYLD, previously shown to 
function in an NF-κB-driven negative feedback loop, nega-
tively regulates Bcl-3 function by preventing its nuclear accu-
mulation and coactivation with both p50 and p52 homodimers 
Figure 4. Regulation of NF-κB  
Transcriptional Activity
(A) In unstimulated cells κB DNA elements may 
be occupied by p50 or p52 homodimers, which 
are unable to recruit coactivator complexes. Re-
lease of canonical p65:p50 dimers in the absence 
of cytoplasmic signaling results in DNA binding 
and HDAC recruitment that may actively repress 
transcription. 
(B) Release of NF-κB dimers through appropri-
ate stimulation is linked to phosphorylation of 
p65, either in the cytoplasm by IKK or PKAc or 
in the nucleus by MSK1/2 or RSK-1. Phospho-
rylated p65 preferentially interacts with CBP/
p300 coactivator complexes resulting in histone 
and p65 acetylation and promotion of target gene 
transcription. 
(C) The exchange of corepressor for coactiva-
tor complexes is additionally catalyzed by IKKα, 
which phosphorylates both CBP/p300-inducing 
preferential binding to NF-κB and corepressor 
complexes inducing HDAC release. 
(D) IKK and MSK may also promote transcription 
through direct phosphorylation of histones. 
(E) Of the many NF-κB gene products, IκB pro-
teins are critically involved in both positive and 
negative feedback responses. Bcl-3 and IκBζ in-
teract with p50- and p52-containing complexes 
and promote transcription of a subset of NF-κB target genes or may stabilize repressive p50 and p52 complexes and repress subsequent rounds of 
NF-κB activation. IκBα and IκBε exert negative feedback by sequestering NF-κB dimers away from DNA. IκBβ function remains unclear.(Massoumi et al., 2006; Simonson et al., 2007). Bcl-3 has also 
recently been implicated in the regulation of p53 by enhancing 
the transcription of Hdm2 in normal and cancer cells (Kashatus 
et al., 2006).
IκBζ has relatively weak homology to other IκBs and is more 
similar to Bcl-3 than the rest of the family. IκBζ is not expressed 
constitutively but rather is upregulated in response to IL-1 and TLR4 
ligands, but not TNF, and upon expression localizes to the nucleus 
(Hayden and Ghosh, 2004). Most intriguingly in the absence of 
IκBζ, LPS- or IL-1-induced expression of a subset of NF-κB-
regulated genes is lost (Yamamoto et al., 2004). IκBζ is induc-
ibly expressed following NF-κB activation and once expressed 
associates primarily with p50 homodimers. Furthermore, IκBζ is 
found associated with p50 on the promoter of IL-6, which is not 
inducibly expressed in IκBζ knockout cells, and it is, therefore, 
hypothesized that IκBζ acts as a coactivator for p50 homodim-
ers (Yamamoto et al., 2004). Although IκBζ does not possess a 
clear TAD or transactivation activity, it does exhibit transactiva-
tion potential when coexpressed as a GAL4 fusion protein with 
GAL4-p50 (Motoyama et al., 2005). IκBζ has also been reported 
to negatively regulate p65-containing NF-κB complexes, and the 
slight elevation of NF-κB activity observed in IκBζ knockouts 
seems consistent with this (Motoyama et al., 2005; Yamamoto et 
al., 2004). Thus IκBζ, like Bcl-3, may also be capable of selectively 
inhibiting or activating specific NF-κB dimers.
Based on the recent progress in understanding IκB functions, 
it is no longer appropriate to generally characterize IκB proteins 
as inhibitors of NF-κB. IκB proteins instead can also act as NF-κB 
cofactors that selectively interact with various NF-κB dimers. 
Through these interactions typical IκBs inhibit NF-κB binding to 
DNA, while the precursor protein p100 can stabilize the formation 
of otherwise unstable NF-κB dimers. The atypical IκBs by stabi-
lizing promoter-bound NF-κB dimers can either inhibit or promote 
NF-κB-driven transcriptional responses (Figure 4).Regulation of Transcription by NF-κB
The five members of the NF-κB family exhibit unique func-
tions; however, the analysis of these functions is greatly com-
plicated by their propensity to form homo- and heterodimers 
thus masking their unique roles in knockout animals. Histori-
cally, much of what we know about the entire NF-κB pathway 
has been discovered using model systems, with stimuli and 
assays that focus on signaling through IκBα to p65-containing 
complexes. As NF-κB research has expanded into ever more 
diverse systems, however, specific functions for individual 
NF-κB subunits and specific dimer pairs are increasingly being 
described (Hoffmann et al., 2006; Natoli et al., 2005). Rather 
than focus on these specific functions, we will discuss more 
general insights into how NF-κB-dependent transcription is 
initiated and terminated.
There are several steps in addition to the IκB degradation that 
are required for complete activation of NF-κB-dependent gene 
expression. Numerous regulatory posttranslational modifica-
tions of NF-κB have been reported. These modifications can be 
directly induced by components of the NF-κB signaling pathway, 
e.g., IKK, and are also important nodes for crosstalk between 
diverse signaling pathways. As in other aspects of NF-κB sig-
naling, posttranslational modifications of p65 are best charac-
terized (Figure 2). Therefore, we will focus on several examples 
of how posttranslational modifications of p65 alter IκB binding, 
affinity for κB sites, and interaction with transcriptional coacti-
vators/repressors. We will outline how NF-κB signaling alters 
transcription through affecting coactivator/repressor activity 
and chromatin modifications before briefly touching upon the 
termination of NF-κB-dependent transcription.
Regulation of Coactivator Binding
Inducible phosphorylation of p65 by protein kinase A (PKA) 
was first recognized more than a decade ago and has since 
been demonstrated to be crucial for NF-κB transcriptional Cell 132, February 8, 2008 ©2008 Elsevier Inc. 355
activity downstream of IκB degradation (Chen and Greene, 
2004). PKA exists in a complex with cytosolic NF-κB:IκB 
complexes and following degradation of IκBα phosphory-
lates p65 at Ser276, promoting the interaction of p65 with the 
transcriptional coactivators CBP (CREB-binding protein) and 
p300 (Zhong et al., 1998). In addition to PKA, other kinases, 
most notably MSK1 and MSK2 (mitogen- and stress-acti-
vated protein kinase), have been reported to phosphorylate 
Ser276 of p65. MSK1 and MSK2 share substrate specific-
ity with PKA, and MSK1−/−MSK2−/− cells have diminished 
transcriptional activity in response to TNF (Vermeulen et 
al., 2003). MSK1/2 are nuclear kinases that are activated by 
multiple pathways including ERK and p38/MAPK and thus 
could mediate crosstalk at the level of p65 or c-Rel, which 
also contains a PKA/MSK1/2 consensus phosphorylation 
site (Perkins, 2006).
Additional p65 phosphorylation events have been 
described, although their mechanistic significance is less 
clear. IKKα and IKKβ have been implicated in the direct 
phosphorylation of p65 at Ser536 (Chen and Greene, 2004; 
Perkins, 2006). Mutation of Ser536 to alanine has been 
reported to abrogate the interaction of p65 with CBP/p300 
(Chen et al., 2005). Ser529 of p65 may also be inducibly 
phosphorylated by CK2 following IL-1 or TNF-α stimula-
tion, although it is unclear whether Ser529 phosphorylation 
affects transcription (Bird et al., 1997; Wang et al., 2000). 
PKCζ can phosphorylate p65 at Ser311, and CBP fails to 
associate with p65 following stimulation of PKCζ-deficient 
cells (Duran et al., 2003). Among the p65 phosphoacceptor 
sites discussed, two occur within the dimerization domain 
of the RHD (serine 276 and serine 311) and two within the 
C-terminal TAD region (serines 529 and 536). It is possible 
that each of these phosphorylation events may contrib-
ute to complete p65 activation by inducing conformational 
changes that facilitate CBP/p300 binding.
Acetylation of p65, probably by CBP/p300 and associ-
ated HATs, occurs in the nucleus and is associated with 
increased transcription (Chen and Greene, 2004). Acetyla-
tion of multiple lysines in p65 has been demonstrated, but 
it is acetylation of Lys310 that has most clearly been shown 
to enhance transcriptional activity without altering binding 
to DNA or IκB (Chen et al., 2002b). Acetylation of Lys310 is 
blocked either in the absence of phosphorylation of Ser276 
or by overexpressing catalytically inactive PKAc (Chen et al., 
2005). Thus p65 phosphorylation is necessary to recruit CBP/
p300 allowing acetylation at Lys310. Ser536 phosphoryla-
tion, while not completely required, significantly enhanced 
Lys310 acetylation (Chen et al., 2005). One possibility is that 
Ser536 phosphorylation alters the interaction of p65 with 
the SMRT (silencing mediator of retinoic acid and thyroid 
hormone receptor) corepressor complex such that the level 
of HDAC3 is decreased and CBP/p300 is increased (Hoberg 
et al., 2006). In addition to p65 phosphorylation, IKKα also 
may promote Lys310 acetylation through direct phosphory-
lation of SMRT, which leads to displacement of HDAC3 from 
the SMRT corepressor complex (Hoberg et al., 2006). IKKα 
regulates transcription through several additional nuclear 
substrates. IKKα is found associated with the κB sites of 356 Cell 132, February 8, 2008 ©2008 Elsevier Inc.some NF-κB-responsive genes, and stimulus-induced 
phosphorylation of histone H3 on serine 10 does not occur 
in the absence of IKKα (Anest et al., 2003; Yamamoto et al., 
2003). In addition to the SMRT and N-CoR (nuclear recep-
tor corepressor) complexes, IKKα also has been shown to 
phosphorylate the CBP coactivator (Huang et al., 2007).
The p53 protein has long been implicated at multiple lev-
els with the NF-κB pathway. The importance of both NF-κB 
and p53 in cancer has promoted significant research into the 
relationship between these two transcription factors. p53 and 
p65 have been reported to directly compete for CBP/p300 
(Webster and Perkins, 1999), which has been suggested to 
promote their crossrepression. However, CBP/p300 is uti-
lized by a wide variety of transcription factors, leaving it 
unclear how two opposing factors directly competing for 
such a crucial resource could account for specific crosstalk 
between two pathways. Instead, modification of the cofactor 
itself might be more relevant. It was recently reported that 
IKKα phosphorylates CBP in a stimulus-dependent manner, 
inducing upregulation of CBP activity, increased binding to 
p65, and decreased binding to p53 (Huang et al., 2007). The 
reciprocal mechanism by which p53 might repress NF-κB is 
less clear, although an analogous conditioning of CBP may 
occur during p53 signaling that is unfavorable for NF-κB/
CBP binding. It would still seem that targeting of CBP by 
IKK might affect transcription factors too broadly; however, 
there may be additional elements, such as the conformation 
of CBP bound with specific transcription factors or the exis-
tence of adapters that might limit the effect of such modifi-
cation to certain groups of transcription factors.
Similar regulation of CBP/p300 might underlie other exam-
ples of transcription factor crosstalk with NF-κB. GSK3β-
deficient embryonic fibroblasts are deficient in NF-κB-
dependent transcriptional activity despite normal nuclear 
translocation and DNA binding (Bonnard et al., 2000; Hoe-
flich et al., 2000). While it has been hypothesized that GSK3β 
might phosphorylate p65, the effect of GSK3β is likely to be 
more indirect. GSK3β, normally constitutively active, phos-
phorylates and inactivates CREB disrupting the interaction 
between CREB and CBP. Thus inactivating GSK3β releases 
repression of CREB, which binds CBP, reducing its access 
to NF-κB (Martin et al., 2005). Interestingly in IKKα−/− cells, 
binding of CBP to CREB is increased (Huang et al., 2007). 
One potential explanation is that CBP bound to CREB is 
a poor substrate for IKKα phosphorylation, and that CBP 
phosphorylated by IKKα binds poorly to CREB. In addition 
to p53 and CREB, there is considerable crosstalk between 
NF-κB and a wide array of transcription factors. The inter-
play between nuclear receptors and NF-κB, which is likely 
to be of considerable physiological significance in under-
standing regulation of inflammation and cancer, is one area 
in which there has been much recent progress (De Bosscher 
et al., 2006).
A surprising aspect of NF-κB-dependent gene expression 
that has emerged recently is that NF-κB-regulated genes can 
be divided into distinct groups depending on their require-
ment for chromatin modification for expression (Natoli et al., 
2005). The first report on this phenomenon classified NF-κB-
dependent genes into constitutively and immediately acces-
sible (CIA) promoters that do not require chromatin modifi-
cation and promoters with regulated and late accessibility 
(RLA) that are dependent on stimulus-induced chromatin 
modification (Saccani et al., 2001). This basic classification 
has been extended to demonstrate that chromatin-remod-
eling complexes are used differentially for inflammatory 
gene expression (Ramirez-Carrozzi et al., 2006). The most 
likely possibility is that the immediate early genes possess 
an open conformation, although what imprints this state of 
chromatin modification remains to be determined. It has 
also been reported recently that mutation of certain phos-
phorylation sites on p65 affects gene expression in a differ-
ential manner. We have recently found in a knockin mouse 
expressing a S276A mutant form of p65 that expression of 
a subset of NF-κB-regulated genes is affected (unpublished 
data). As Ser276 is critical for recruitment of CBP, this sug-
gests that different NF-κB-regulated genes differ in their 
requirement for histone acetylation, although the basis of 
this difference remains unclear. While it has been shown that 
κB site sequence may, in some cases, determine cofactor 
binding, more general rules governing cofactor binding have 
yet to be determined (Leung et al., 2004). In addition to tra-
ditional coactivator and corepressor complexes, there is a 
growing list of proteins that interact with NF-κB dimers and 
affect DNA binding and transcription (Natoli et al., 2005). 
One recent and intriguing addition to this list is ribosomal 
protein S3 (RPS3), which seems to be required for the bind-
ing of NF-κB at specific κB sites (Wan et al., 2007)
In addition to coactivator requirements, the specific func-
tion of individual NF-κB dimers is coming under increased 
scrutiny (Hoffmann et al., 2003, 2006). For example, while 
it has been shown that certain dimers show differences in 
κB binding site affinity in vitro, analyses of promoter bind-
ing in vivo suggest that dimer selection cannot be reduced 
to κB sequence alone (Bonizzi et al., 2004; Britanova et al., 
2008; Schreiber et al., 2006). Temporal differences in dimer 
release, due in part to selective IκB binding; pathway and 
cell type-specific posttranslation modifications of NF-κB 
subunits; coordination with other inducible transcription 
factor pathways; and the complex nature of promoter struc-
tures among other factors are probably important. It is likely, 
however, that exploration of the mechanism by which NF-κB 
dimers interface with chromatin in gene expression will be a 
major area of investigation in the future.
Shutting off NF-κB
The mechanisms by which activity of NF-κB is terminated 
remain poorly understood. To date most efforts in this area 
have focused on mechanisms that involve IκB proteins and 
upstream signaling intermediates (Hacker and Karin, 2006; 
Hayden and Ghosh, 2004). However, none of these mecha-
nisms explain how active, DNA-bound NF-κB is suppressed 
once signaling is terminated. Therefore, while IκB resyn-
thesis and induction of other gene products impinging on 
upstream signaling components are clearly critical elements 
in NF-κB downregulation, there are likely additional mecha-
nisms that function later in the pathway. One possibility is 
that promoter-bound p65 may be subject to proteasomal degradation (Saccani et al., 2004). In LPS signaling, suppres-
sor of cytokine signaling-1 (SOCS-1), in addition to its effects 
on upstream JAK-STAT signaling components, decreases 
NF-κB transcriptional activity (Kinjyo et al., 2002; Naka-
gawa et al., 2002). Although the exact mechanism of action 
remains unclear, it has recently been shown that targeting 
the SOCS-1-containing ubiquitin ligase complex (ECSSOCS1) 
to p65-containing dimers is carried out by COMMD1 (Copper 
Metabolism MURR1 Domain containing-1) proteins (Maine 
et al., 2007). IKKα is also involved in termination of inflam-
matory transcriptional responses in macrophages, possi-
bly by promoting the nuclear degradation of both p65 and 
c-Rel (Lawrence et al., 2005; Li et al., 2005). Because IKKα 
is required for activating NF-κB-dependent transcriptional 
responses, it seemed unclear whether IKKα acts directly on 
NF-κB to repress the latter stages of transcription or acts by 
supporting the expression of gene products that act in nega-
tive feedback pathways. However, the recent demonstration 
that IKKα represses transcription of the tumor suppressor 
Maspin by acting at the maspin promoter strongly supports 
a direct mechanism of action by IKKα that is independent of 
NF-κB (Luo et al., 2007). These findings, along with several 
other recent reports that have focused on negative regula-
tion of nuclear NF-κB, suggest that this aspect of NF-κB 
regulation will be an area of significant activity in the near 
future.
Concluding Remarks
As a result of the tremendous progress made over the past 
20 years or so, several common themes have emerged as 
being essential to all NF-κB signaling. Yet, there are still 
major unanswered questions about the biology and regula-
tion of NF-κB. These include questions about the regulation 
of different NF-κB dimers, the exact role of ubiquitination as 
a regulatory event in signaling, the additional roles of differ-
ent IκB isoforms, and novel roles for IKKs in pathways other 
than NF-κB. The interaction between chromatin and NF-κB 
in regulating gene expression programs is also likely to be an 
area of intense investigation, as are the events that terminate 
NF-κB signaling. Several of these areas promise to provide 
significant insight into signaling and transcriptional regulation 
that will impact our understanding of these processes both 
within and beyond the field of NF-κB. Although we have not 
been able to discuss it the current Review, the link between 
NF-κB and different aspects of physiology keep emerging. 
For example, a recent report (Adler et al., 2007) has provided 
evidence that NF-κB plays an important role in aging of the 
skin. As inflammatory processes are believed to contribute to 
aging phenomenon in general, it will probably not be surpris-
ing that one method of slowing aging may lie in selectively 
blocking NF-κB-dependent inflammatory processes. Along 
with the already well-established links between NF-κB and 
diseases such as cancer, asthma, and muscular dystrophy 
(Acharyya et al., 2007), it is clear that the major advances in 
the near future will come from the ability to develop effec-
tive inhibitors of the NF-κB pathway that can act selectively, 
thereby avoiding the risk of undesired side effects. The over-
lapping roles played by NF-κB pathway components in varied Cell 132, February 8, 2008 ©2008 Elsevier Inc. 357
physiological settings suggest that this task will be both cru-
cial and difficult. However, it is not too far-fetched to imagine 
a future where we will have a series of NF-κB inhibitors aimed 
at different diseases, based on their ability to target specific 
pathways or cells, and therefore we anticipate that interest 
and excitement in this most versatile of transcription factors 
will continue at the same pace.
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